EMA’s API general terms and conditions of use - Terms of use

Medicines for human use under evaluation

Updates to industry contact management for authorisation products (IRIS), Online, European Medicines Agency, Amsterdam, the Netherlands, from 11 June 2026, 11:00 (CEST) to 11 June 2026, 12:15 (CEST)

Referral: Tecovirimat SIGA, tecovirimat Article 20 procedures European Commission final decision, 26/03/2026, 29/05/2026, 02/06/2026

Human medicines European public assessment report (EPAR): Theralugand, lutetium (177Lu) chloride, Date of authorisation: 22/11/2024, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Orkambi, lumacaftor,ivacaftor, Date of authorisation: 19/11/2015, Revision: 39, Status: Authorised

Questions and answers on the refusal of a change to the marketing authorisation for Hetlioz (tasimelteon) (II-40)

Website outages and upgrades

Human medicines European public assessment report (EPAR): Pazenir, paclitaxel, Date of authorisation: 06/05/2019, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Opdivo, nivolumab, Date of authorisation: 19/06/2015, Revision: 74, Status: Authorised